UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Asparaginase products in upfront acute lymphoblastic leukemia therapy: Value, location, and style

Pediatric blood & cancer, 2019-01, Vol.66 (1), p.e27497-n/a

Russell, Heidi V.

2019

Volltextzugriff (PDF)

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

Nature medicine, 2008-11, Vol.14 (11), p.1264-1270

2008

Volltextzugriff (PDF)

Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma

Blood, 2011-12, Vol.118 (23), p.6050-6056

2011

Volltextzugriff (PDF)

Payer and race/ethnicity influence length and cost of childhood cancer hospitalizations

Pediatric blood & cancer, 2019-07, Vol.66 (7), p.e27739-n/a

2019

Volltextzugriff (PDF)

Mental distress and health care use among survivors of adolescent and young adult cancer: A cross‐sectional analysis of the National Health Interview Survey

Cancer, 2017-03, Vol.123 (5), p.869-878

2017

Volltextzugriff (PDF)

Parent-Reported Clinical Utility of Pediatric Genomic Sequencing

Pediatrics (Evanston), 2023-08, Vol.152 (2), p.1

2023

Volltextzugriff (PDF)

Rising drug cost impacts on cost‐effectiveness of 2 chemotherapy regimens for intermediate‐risk rhabdomyosarcoma: A report from the Children's Oncology Group

Cancer, 2022-01, Vol.128 (2), p.317-325

2022

Volltextzugriff (PDF)

Clinical Application of Genome and Exome Sequencing as a Diagnostic Tool for Pediatric Patients: a Scoping Review of the Literature

Genetics in medicine, 2019-01, Vol.21 (1), p.3-16

2019

Volltextzugriff (PDF)

US private payers’ perspectives on insurance coverage for genome sequencing versus exome sequencing: A study by the Clinical Sequencing Evidence-Generating Research Consortium (CSER)

Genetics in medicine, 2022-01, Vol.24 (1), p.238-244

2022

Volltextzugriff (PDF)

Neuroblastoma of the Bone and Bone Marrow Without an Apparent Primary Site: Report of 4 Cases With Long-term Follow-up

Pediatric and developmental pathology, 2019-07, Vol.22 (4), p.329-333

2019

Volltextzugriff (PDF)

Healthcare Spending and Systemic Bevacizumab for Recurrent Respiratory Papillomatosis

Journal of voice, 2024-04

2024

Volltextzugriff (PDF)

Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells

Cancer research (Chicago, Ill.), 2009-01, Vol.69 (1), p.329-337

2009

Volltextzugriff (PDF)

Using the Delphi method to identify clinicians’ perceived importance of pediatric exome sequencing results

Genetics in medicine, 2020, Vol.22 (1), p.69-76

2020

Volltextzugriff (PDF)

Factors Influencing Family Burden in Pediatric Hematology/Oncology Encounters

Journal of patient-centered research and reviews, 2019-10, Vol.6 (4), p.243-251

2019

Volltextzugriff (PDF)

Exome sequencing compared with standard genetic tests for critically ill infants with suspected genetic conditions

Genetics in medicine, 2020-08, Vol.22 (8), p.1303-1310

2020

Volltextzugriff (PDF)

Radiation Therapy to the Primary and Postinduction Chemotherapy MIBG-Avid Sites in High-Risk Neuroblastoma

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (4), p.858-862

2014

Volltextzugriff (PDF)

Is high‐risk neuroblastoma induction chemotherapy possible without G‐CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors

Pediatric blood & cancer, 2020-10, Vol.67 (10), p.e28417-n/a

2020

Volltextzugriff (PDF)

Cost-effectiveness frameworks for comparing genome and exome sequencing versus conventional diagnostic pathways: A scoping review and recommended methods

Genetics in medicine, 2022-10, Vol.24 (10), p.2014-2027

2022

Volltextzugriff (PDF)

Economic evaluation of pediatric cancer treatment: a systematic literature review

Pediatrics (Evanston), 2013-01, Vol.131 (1), p.e273-e287

2013

Volltextzugriff (PDF)

Incidence and risk factors of bacterial and fungal infection during induction chemotherapy for high-risk neuroblastoma

Pediatric hematology and oncology, 2017-07, Vol.34 (5), p.331-342

2017

Volltextzugriff (PDF)

Using decision modeling to guide drug allocation during a shortage

Pediatric blood & cancer, 2017-07, Vol.64 (7), p.n/a

2017

Volltextzugriff (PDF)

The optimal timing of surgical resection in high-risk neuroblastoma

Journal of pediatric surgery, 2016-10, Vol.51 (10), p.1665-1669

2016

Volltextzugriff (PDF)

Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma

Molecular cancer therapeutics, 2009-08, Vol.8 (8), p.2461-2469

2009

Volltextzugriff (PDF)

Blood product administration during high risk neuroblastoma therapy

Pediatric hematology and oncology, 2020-01, Vol.37 (1), p.5-14

2020

Volltextzugriff (PDF)

Treatment of nasopharyngeal carcinoma with Epstein-Barr virus–specific T lymphocytes

Blood, 2005-03, Vol.105 (5), p.1898-1904

2005

Volltextzugriff (PDF)

1 – 25 von 544

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(492)
Mit Volltextzugriff
(440)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(542)
Spanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Asparaginase products in upfront acute lymphoblastic leukemia therapy: Value, location, and style

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma

Payer and race/ethnicity influence length and cost of childhood cancer hospitalizations

Mental distress and health care use among survivors of adolescent and young adult cancer: A cross‐sectional analysis of the National Health Interview Survey

Parent-Reported Clinical Utility of Pediatric Genomic Sequencing

Rising drug cost impacts on cost‐effectiveness of 2 chemotherapy regimens for intermediate‐risk rhabdomyosarcoma: A report from the Children's Oncology Group

Clinical Application of Genome and Exome Sequencing as a Diagnostic Tool for Pediatric Patients: a Scoping Review of the Literature

US private payers’ perspectives on insurance coverage for genome sequencing versus exome sequencing: A study by the Clinical Sequencing Evidence-Generating Research Consortium (CSER)

Neuroblastoma of the Bone and Bone Marrow Without an Apparent Primary Site: Report of 4 Cases With Long-term Follow-up

Healthcare Spending and Systemic Bevacizumab for Recurrent Respiratory Papillomatosis

Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells

Using the Delphi method to identify clinicians’ perceived importance of pediatric exome sequencing results

Factors Influencing Family Burden in Pediatric Hematology/Oncology Encounters

Exome sequencing compared with standard genetic tests for critically ill infants with suspected genetic conditions

Radiation Therapy to the Primary and Postinduction Chemotherapy MIBG-Avid Sites in High-Risk Neuroblastoma

Is high‐risk neuroblastoma induction chemotherapy possible without G‐CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors

Cost-effectiveness frameworks for comparing genome and exome sequencing versus conventional diagnostic pathways: A scoping review and recommended methods

Economic evaluation of pediatric cancer treatment: a systematic literature review

Incidence and risk factors of bacterial and fungal infection during induction chemotherapy for high-risk neuroblastoma

Using decision modeling to guide drug allocation during a shortage

The optimal timing of surgical resection in high-risk neuroblastoma

Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma

Blood product administration during high risk neuroblastoma therapy

Treatment of nasopharyngeal carcinoma with Epstein-Barr virus–specific T lymphocytes

Suchergebnisse filtern